NCT00003075View on ClinicalTrials.gov

Fenretinide in Treating Patients With Cervical Neoplasia

PHASE3CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 5, 1993

Primary Completion Date

May 1, 2001

Study Completion Date

May 1, 2001

Conditions
Cervical CancerPrecancerous Condition
Interventions
DRUG

Fenretinide

Oral Fenretinide daily for 6 months with 3 days of rest every month.

OTHER

Placebo

Oral placebo daily for 6 months with 3 days of rest every month.

Trial Locations (1)

77030

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00003075 - Fenretinide in Treating Patients With Cervical Neoplasia | Biotech Hunter | Biotech Hunter